Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
12 juin 2024 09h05 HE
|
Revive Therapeutics Ltd.
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy
30 mai 2024 04h30 HE
|
CROSSJECT
L’étude clinique réalisée en 2022 est maintenant publiée dans la revue à comité de lecture Neurology and Therapy Plus de details sur la bioéquivalence démontrée par rapport au...
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
30 mai 2024 04h30 HE
|
CROSSJECT
Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum® Early...
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
23 mai 2024 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and...
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
01 mai 2024 08h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
23 avr. 2024 07h00 HE
|
Revive Therapeutics Ltd.
TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
04 avr. 2024 09h04 HE
|
RapidPulse, Inc
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
02 avr. 2024 07h30 HE
|
Revive Therapeutics Ltd.
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
19 mars 2024 07h00 HE
|
Revive Therapeutics Ltd.
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study
28 févr. 2024 07h00 HE
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study....